171 related articles for article (PubMed ID: 24581432)
21. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma.
Thomson NC
Evid Based Med; 2014 Aug; 19(4):135. PubMed ID: 24627175
[No Abstract] [Full Text] [Related]
23. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
24. Omalizumab and hypersensitivity reactions.
Shankar T; Petrov AA
Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
[TBL] [Abstract][Full Text] [Related]
25. [A case of severe asthma and peach allergy that improved with omalizumab therapy: a case report].
Suzuki S; Matsuura T; Kimura T; Tazaki T; Fukuda M; Homma T; Matsukura S; Kurokawa M; Adachi M
Arerugi; 2012 Feb; 61(2):215-23. PubMed ID: 22437731
[TBL] [Abstract][Full Text] [Related]
26. Potential treatments for food allergy.
Albin S; Nowak-Węgrzyn A
Immunol Allergy Clin North Am; 2015 Feb; 35(1):77-100. PubMed ID: 25459578
[TBL] [Abstract][Full Text] [Related]
27. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
Chen H; Eisner MD; Haselkorn T; Trzaskoma B
Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
[TBL] [Abstract][Full Text] [Related]
28. [The add-on effect of omalizumab on patients with uncontrolled bronchial asthma].
Minami Y; Endo S; Okumur S; Sasaki T; Yamamoto Y; Ogasa T; Osanai S; Ohsaki Y
Nihon Kokyuki Gakkai Zasshi; 2011 Nov; 49(11):793-9. PubMed ID: 22171481
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Asthma--do we need more innovation for treatment?
Riedler J
Pediatr Allergy Immunol; 2014 Feb; 25(1):19-20. PubMed ID: 24588482
[No Abstract] [Full Text] [Related]
30. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
31. Summaries for patients. Omalizumab therapy for patients with severe asthma.
Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934
[No Abstract] [Full Text] [Related]
32. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
34. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
36. [A case of an asthma patient receiving omalizumab during pregnancy].
Hirashima J; Hojo M; Iikura M; Hiraishi Y; Nakamichi S; Sugiyama H; Kobayashi N; Kudo K
Arerugi; 2012 Nov; 61(11):1683-7. PubMed ID: 23328225
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.
Eisner MD; Zazzali JL; Miller MK; Bradley MS; Schatz M
J Asthma; 2012 Aug; 49(6):642-8. PubMed ID: 22793527
[TBL] [Abstract][Full Text] [Related]
38. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
39. Anti-IgE for asthma in inner-city children.
Geraci C; Longo G
N Engl J Med; 2011 Jun; 364(26):2557; author reply 2557-8. PubMed ID: 21714663
[No Abstract] [Full Text] [Related]
40. Association between consistent omalizumab treatment and asthma control.
Lafeuille MH; Gravel J; Zhang J; Gorsh B; Figliomeni M; Lefebvre P
J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
